Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.
1 . An antibody, comprising:
an anti-claudin 18.2 (CLDN18.2) unit having binding specificity to a CLDN18.2 protein, wherein the anti-CLDN18.2 unit comprises a heavy chain variable region (VH) comprising a CDRH1, a CDRH2, and a CDRH3, and a light chain variable region (VL) comprising a CDRL1, a CDRL2 and a CDRL3, wherein:
(a) the CDRH1 comprises the amino acid sequence of SEQ ID NO:7:
the CDRH2 comprises the amino acid sequence of SEQ ID NO:8;
the CDRH3 comprises the amino acid sequence of SEQ ID NO:9;
the CDRL1 comprises the amino acid sequence of SEQ ID NO:10;
the CDRL2 comprises the amino acid sequence of SEQ ID NO:11; and
and the CDRL3 comprises the amino acid sequence of SEQ ID NO:12;
(b) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 13;
the CDRH2 comprises the amino acid sequence of SEQ ID NO:14;
the CDRH3 comprises the amino acid sequence of SEQ ID NO:15;
the CDRL1 comprises the amino acid sequence of SEQ ID NO:16;
the CDRL2 comprises the amino acid sequence of SEQ ID NO: 17; and
and the CDRL3 comprises the amino acid sequence of SEQ ID NO:18; or
(c) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 19;
the CDRH2 comprises the amino acid sequence of SEQ ID NO:20;
the CDRH3 comprises the amino acid sequence of SEQ ID NO:21;
the CDRL1 comprises the amino acid sequence of SEQ ID NO:22;
the CDRL2 comprises the amino acid sequence of SEQ ID NO:11; and
the CDRL3 comprises the amino acid sequence of SEQ ID NO:23; and
an anti-4-1BB unit having binding specificity to a 4-1BB protein, wherein the anti-4-1BB unit comprises a heavy chain variable region (VH) comprising a CDRH1, a CDRH2, and a CDRH3, and a light chain variable region (VL) comprising a CDRL1, a CDRL2 and a CDRL3, and wherein:
the CDRH1 comprises the amino acid sequence of SEQ ID NO:60;
the CDRH2 comprises the amino acid sequence of SEQ ID NO:61;
the CDRH3 comprises the amino acid sequence of SEQ ID NO:62;
the CDRL1 comprises the amino acid sequence of SEQ ID NO:4;
the CDRL2 comprises the amino acid sequence of SEQ ID NO:5; and
the CDRL3 comprises the amino acid sequence of SEQ ID NO:6.
2 . The antibody of claim 1 , wherein the binding of the anti-4-1BB unit to 4-1BB proteins on a cell does not result in clustering of the 4-1BB proteins, in the absence of the anti-CLDN18.2 unit binding to a CLDN18.2 protein.
3 . The antibody of claim 1 , further comprising a Fc fragment that has reduced effector function.
4 . The antibody of claim 3 , wherein the Fc fragment is selected from the group consisting of:
an IgG1 Fc fragment with a L235E mutation,
an IgG1 Fc fragment with a L234A and/or L235A mutation,
an IgG1 Fc fragment with a P329G or P329A mutation,
an IgG4 Fc fragment with a F234A and/or L235A or L235E mutation,
an IgG2 Fc fragment with a H268Q, V309L, A330S, and/or P33 1 S mutation, and
an IgG2 Fc fragment with a V234A, G237A, P238S, H268A, V309L, A330S, and/or P331S mutation (EU numbering).
5 . The antibody of claim 1 , wherein the VH of the anti-4-1BB unit comprises an amino acid sequence selected from the group consisting of SEQ ID NO:51, 67 and 68 and the VL of the anti-4-1BB unit comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, 52-53 and 69-74.
6 . The antibody of claim 1 , wherein the VH of the anti-CLDN18.2 unit comprises an amino acid sequence selected from the group consisting of SEQ ID NO:26, 28 and 30, and the VL of the anti-CLDN18.2 unit comprises an amino acid sequence selected from the group consisting of SEQ ID NO:27, 29 and 31.
7 . An antibody comprising two first polypeptides and two second polypeptides,
wherein each first polypeptide comprises, from N- to C-terminus, a heavy chain variable region (VH), a CH1, a CH2, a CH3, and a single chain fragment (scFv) having specificity to a 4-1BB protein;
wherein each second polypeptide comprises a light chain variable region (VL) and a light chain constant region (CL);
wherein each VH is paired with one of the VL and has specificity to a claudin 18.2 (CLDN18.2) protein;
wherein the VH of the VH/VL pair comprises a CDRH1, a CDRH2, and a CDRH3, and the VL of the VH/VL pair comprises a CDRL1, a CDRL2 and a CDRL3, wherein:
(a) the CDRH1 comprises the amino acid sequence of SEQ ID NO:7;
the CDRH2 comprises the amino acid sequence of SEQ ID NO:8;
the CDRH3 comprises the amino acid sequence of SEQ ID NO:9;
the CDRL1 comprises the amino acid sequence of SEQ ID NO:10;
the CDRL2 comprises the amino acid sequence of SEQ ID NO:11; and
the CDRL3 comprises the amino acid sequence of SEQ ID NO:12;
(b) the CDRH1 comprises the amino acid sequence of SEQ ID NO:13;
the CDRH2 comprises the amino acid sequence of SEQ ID NO:14;
the CDRH3 comprises the amino acid sequence of SEQ ID NO:15;
the CDRL1 comprises the amino acid sequence of SEQ ID NO:16;
the CDRL2 comprises the amino acid sequence of SEQ ID NO: 17; and
the CDRL3 comprises the amino acid sequence of SEQ ID NO: 18; or
(c) the CDRH1 comprises the amino acid sequence of SEQ ID NO: 19;
the CDRH2 comprises the amino acid sequence of SEQ ID NO:20;
the CDRH3 comprises the amino acid sequence of SEQ ID NO:21;
the CDRL1 comprises the amino acid sequence of SEQ ID NO:22;
the CDRL2 comprises the amino acid sequence of SEQ ID NO: 11; and
the CDRL3 comprises the amino acid sequence of SEQ ID NO:23; and
wherein the scFv comprises a heavy chain variable region (VH) comprising a CDRH1, a CDRH2, and a CDRH3, and a light chain variable region (VL) comprising a CDRL1, a CDRL2 and a CDRL3, wherein:
the CDRH1 comprises the amino acid sequence of SEQ ID NO:60;
the CDRH2 comprises the amino acid sequence of SEQ ID NO:61;
the CDRH3 comprises the amino acid sequence of SEQ ID NO:62;
the CDRL1 comprises the amino acid sequence of SEQ ID NO:4;
the CDRL2 comprises the amino acid sequence of SEQ ID NO:5; and
the CDRL3 comprises the amino acid sequence of SEQ ID NO:6.
8 . The antibody of claim 7 , wherein the VH of the scFv comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 51, 67 and 68 and the VL of the scFv comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, 52-53 and 69-74.
9 . The antibody of claim 7 , wherein the VH of the VH/VL pair comprises an amino acid sequence selected from the group consisting of SEQ ID NO:26, 28 and 30, and the VL of the VH/VL pair comprises an amino acid sequence selected from the group consisting of SEQ ID NO:27, 29 and 31.
10 . One or more polynucleotides encoding the antibody of claim 1 .
11 . One or more polynucleotides encoding the antibody of claim 7 .
12 . A method for treating a CLDN18.2-positive cancer in a patient in need thereof, comprising administering to the patient the antibody of claim 1 .
13 . The method of claim 12 , wherein the cancer is an epithelial tumor, or wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, head and neck cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, pancreatic cancer, prostate cancer, and thyroid cancer.
14 . A method for treating a CLDN18.2-positive cancer in a patient in need thereof, comprising administering to the patient the antibody of claim 8 .
15 . The method of claim 14 , wherein the cancer is an epithelial tumor, or wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, head and neck cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, pancreatic cancer, prostate cancer, and thyroid cancer.